Background and Purpose: Nimodipine, a calcium antagonist, has been reported to have beneficial effects in acute ischemic infarction. Some calcium channel antagonists have antiplatelet effects. We investigated the effect of oral nimodipine on platelet function in healthy volunteers.
In recent years calcium antagonists have been proposed as therapy for cerebrovascular disease.1-8
The properties of calcium antagonists that may be beneficial in cerebrovascular disease include vasodilation of cerebral vessels38 and reduction of Ca2+ entry into neurons. 138 Nimodipine, a dihydropyridine derivative, has been approved in the United States for treatment of ischemia after subarachnoid hemorrhage.8'9 A beneficial effect of nimodipine has been suggested in acute ischemic stroke, although clinical trials have produced conflicting results. 12, 4, 5, 7, 8 A recent meta-analysis of the acute infarction trials suggested a beneficial effect only if treatment with nimodipine was begun within 12 hours of onset of ischemia. 6 Calcium antagonists have also been noted to have antiplatelet effects,'0-15 a property that might be important in the treatment of cerebral ischemia. The antiplatelet properties appear to vary among differing calcium antagonists.12"'415 Calcium antagonists may inhibit ex vivo platelet aggregation in response to collagen, epinephrine, and serotonin and cause mild prolongation of the bleeding time'0-1316 Because nimodipine's antiplatelet activity has not been extensively studied, we examined the effect of nimodipine on platelet function in a group of normal subjects.
Subjects and Methods
Twelve healthy volunteer subjects, 6 men and 6 women, participated in this study. The mean+SD age was 32.9+5.6 (range, 24-44) years. The subjects were instructed not to take any other medication for 2 weeks before the start of the study or during the 9 days of the study. They were specifically questioned about aspirincontaining compounds and nonsteroidal anti-inflammatory drugs. Informed consent was obtained from all subjects.
Baseline laboratory tests (chemistry panel, complete blood count, platelet count, and pregnancy test) were used to rule out underlying disease or pregnancy. A bleeding time test was performed using a Simplate II device (Organon Teknika, Durham, N.C.) before ingestion of any drug and 1 hour after the ingestion of the final dose.
During the initial study period, subjects took 30 mg nimodipine (Miles Inc., West Haven, Conn.) every 6 hours for a 24-hour period (120 mg/day). Blood for platelet aggregation and adenosine triphosphate (ATP) release was drawn in the morning before the first dose and after a low-fat breakfast (first baseline sample). Blood was obtained 1 hour after the first dose, and again the next morning 1 hour after ingestion of the last dose of nimodipine.
The subjects then took no medications for 1 week, followed by 60 mg nimodipine taken every 6 hours for a 24-hour period (240 mg/day). Blood for platelet aggregation studies and ATP release was again obtained before the first 60-mg dose of nimodipine (second baseline sample), 1 hour after the first dose, and 1 hour after the final dose. A second bleeding time test was performed 1 hour after the last 60-mg dose of nimodipine. Using a 21G butterfly needle, 22.5 ml blood was drawn into a syringe containing 2.5 ml 3.8% sodium citrate anticoagulant. Platelet-rich plasma was prepared and adjusted with platelet poor plasma to 2x 105/mm3 platelets. A model 660 dual-chamber platelet ionized calcium aggregometer was used. Agonists used were thrombin, collagen, adenosine diphosphate (ADP), and epinephrine. Chrono-Lume reagent was used to determine the ATP release. All reagents and the platelet aggregometer were products of Chrono-Log (Havertown, Pa.).
For platelet aggregation studies, 450-,ul aliquots of platelet-rich plasma were pipetted into siliconized glass cuvettes. Individual cuvettes were allowed to warm to 37°C for at least 2 minutes but not more than 5 minutes. Fifty microliters of Chrono-Lume was added to the cuvette in the mixing chamber and allowed to equilibrate for 1 minute before the addition of the agonist. Final cuvette concentrations were as follows: thrombin 1 IU/mI, collagen 2 ,ug!ml, epinephrine 10 Platelet aggregation studies were performed in control subjects (n=3) before and after aspirin ingestion. Aspirin abolished platelet aggregation in response to collagen and epinephrine and second-phase aggregation in response to ADP in all controls.
Platelet aggregation and ATP release (in response to the above agonists) at each dosage strength of nimodipine were compared with baseline values using Student's two-tailed paired t test. Bleeding times at baseline and after 60 mg nimodipine were also compared using Student's two-tailed paired t test. Primary aggregation rates in response to ADP were also compared with baseline using Student's two-tailed paired t test. Threshold ADP concentration at each dosage strength was compared with baseline using the Wilcoxon signed rank test. Significance was sought at the a=0.05 level.
Results
Baseline blood tests revealed no underlying disease or pregnancy. The mean platelet count was 2.56±0.57x 105/ mm3 platelets (range, 1.51-3.72x 105/mm3; laboratory normal range, 1.5-3.5 x 105/mm3 platelets).
Percent aggregation in response to collagen, epinephrine, and ADP at each time period and nimodipine dosage is shown in Table 1 . There were no significant differences noted at any time at 120 mg/day. At 240 mg/day, there was a minor decrease in aggregation in response to 10 ,M ADP after the first 60-mg dose (p=0.038) but not after 24 hours. There was no significant change in the maximum primary aggregation rate in response to 2.5 or 5 ,uM ADP at either nimodipine dosage.
ATP release at each time period and dosage strength is shown in Table 2 . No significant differences were noted at a dose of 120 mg/day. ATP release in response to 10 juM ADP at 1 hour after the first 60-mg dose of nimodipine showed a significant decline from baseline (0.50±0.08 nmol versus 0.28±0.05 nmol; p=0.001). At 24 hours, after the fourth 60-mg dose of nimodipine, this appeared to recover slightly but was still signifi- cantly different from baseline (0.50±0.08 nmol versus 0.29±0.06 nmol; p=0.008) (Figure 1) .
Threshold ADP concentration for second-phase platelet aggregation is shown in Figure 2 . After 24 hours of 60-mg doses of nimodipine, threshold was increased in three subjects, decreased in one, and unchanged in six. These differences were not statistically significant. Threshold dose was not significantly different from baseline at any time period or nimodipine dosage.
Levels of TXB2 are shown in Only minor effects on platelet function were seen at a dose of 240 mg/day. There was a slight decrease in ADP-induced ATP release seen only with a suprathreshold (10 ,uM) concentration of ADP after the first 60-mg nimodipine dose when compared with the second baseline value. Of note, the second baseline value for ADP release showed a slight increase from the first baseline value; if ADP release in response to 10 ,uM is compared with the original baseline, there is no significant decrease ( Table 2) .
Because of the small number of patients in this study, we may have missed a small but statistically significant effect on platelet function. However, we do not feel that we have missed a clinically significant effect. Clinical trials have reported a beneficial effect of nimodipine at a dose of 120 mg/day,2.6'7 and we saw no evidence of any antiplatelet effect at this dose.
Several caveats apply to this study. The effect of nimodipine ex vivo may be different from that in vivo. 
